Drug Trial Radar · NCT04125732
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
Last checked: Nov 19, 2026Latest source record: Jan 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Jan 24, 2020
Primary completion
Jan 31, 2023
Study completion May 30, 2023
Sponsor
- Lead sponsor
- XyloCor Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).
Conditions
- Coronary Artery Disease
- Ischemia
- Angina Refractory
- Cardiovascular Diseases
- Heart Diseases
Interventions
AdVEGFXC1Biological
AdVEGFXC1 at one of 4 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Endpoint (adverse events)Time frame: 6 months
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Cardiology Research Associates
Daytona Beach, Florida
University of Florida
Gainesville, Florida
James A. Haley VA Medical Center
Tampa, Florida
Emory University
Atlanta, Georgia
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota
Duke University
Durham, North Carolina
The Christ Hospital / The Lindner Research Center
Cincinnati, Ohio
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Lehigh Valley Health Network
Allentown, Pennsylvania
Houston Methodist
Houston, Texas
Texas Heart Institute
Houston, Texas
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.